Annual Report • Feb 23, 2016
Annual Report
Open in ViewerOpens in native device viewer
Te verspreiden op dinsdag 23 februari 2016 Continental Time 07.30h. U.K. 06.30h. / U.S. Eastern Standard Time 01.30h.
"Het jaar 2015 was voor DOCDATA N.V. een uitdagend en bewogen jaar. Er waren uitdagingen aan de business kant, de herstructurering van IAI industrial systems en de sterke groei van het e-commerce bedrijf Docdata. Daarnaast is in de loop van 2015 de verkoop van het e-commerce bedrijf Docdata in een stroomversnelling geraakt en hebben wij als gevolg daarvan besloten om ook IAI te verkopen, teneinde de continuïteit van dit bedrijfsonderdeel te kunnen waarborgen. Dit heeft geresulteerd in twee deals die in een periode van amper 6 maanden zijn gerealiseerd. Wij kijken terug op een succesvol jaar; voor onze medewerkers, onze klanten en uiteraard ook voor onze aandeelhouders. Ik wil eenieder danken voor de samenwerking en het succes dat we in de afgelopen 15 jaar samen hebben gerealiseerd."
De belangrijkste financiële resultaten die door DOCDATA N.V. zijn gerealiseerd in 2015, alsmede de financiële positie, kunnen als volgt worden samengevat:
• De balans per 31 december 2015 van DOCDATA N.V. is als gevolg van de beide verkooptransacties aanzienlijk vereenvoudigd in vergelijking met het voorgaande jaar. Naast de eerdergenoemde kortlopende belastingvordering bestaan de vlottende activa uit een banktegoed van € 31,8 miljoen en overige vorderingen van € 0,3 miljoen (totaal activa: € 33,3 miljoen). De kortlopende verplichtingen bedragen in totaal € 28,3 miljoen, waarin opgenomen de in januari 2016 aan de aandeelhouders uit te betalen aanvullende interim-uitkering van € 17,5 miljoen, crediteuren en overige schulden van € 9,3 miljoen (voornamelijk nog te betalen transactiekosten) en een voorziening voor beëindigingsvergoedingen inzake opgezegde arbeidsovereenkomsten van € 1,5 miljoen (totaal verplichtingen: € 28,3 miljoen). Het eigen vermogen van DOCDATA N.V. bedraagt € 5,0 miljoen per 31 december 2015, waarmee de solvabiliteitsratio is gedaald tot 15,1% (31 december 2014: 44,6%) als gevolg van de interim-uitkeringen waartoe is besloten door de Buitengewone Algemene Vergadering van Aandeelhouders op 16 december 2015 na de verkoop van de Docdata Groep en de IAI Groep.
Het banktegoed van DOCDATA N.V. bedraagt op dit moment nog € 7 miljoen, nadat in de periode sinds 31 december 2015 (banktegoed: € 31,8 miljoen) uitgaven zijn gedaan voor:
Het banktegoed op dit moment van € 7 miljoen zal worden aangewend om de lopende kosten in 2016, alsmede de overige lopende verplichtingen van de beursholding af te wikkelen. Thans verwacht de Directie dat uiteindelijk, naar alle waarschijnlijkheid, een bedrag van ongeveer € 3,9 miljoen zal resteren in de beursholding. Hierbij is geen rekening gehouden met de aandeelhouderswaarde die gerealiseerd wordt bij een mogelijke verkoop van de aandelen van de beursholding.
Het jaar 2016 zal voor DOCDATA N.V. in het teken staan van de verkoop, dan wel de opheffing van de beursholding. In dit kader is inmiddels onder leiding van de CFO een traject opgestart, dat zal worden begeleid door NIBC Bank N.V. als Corporate Finance adviseur en NautaDutilh N.V. als juridisch adviseur van de beursholding.
De Directie en de Raad van Commissarissen streven ernaar om in de jaarlijkse Algemene Vergadering van Aandeelhouders, welke zal worden gehouden op woensdag 11 mei 2016, een uitgewerkt voorstel aan de aandeelhouders ter goedkeuring te kunnen voorleggen. De agenda voor deze aandeelhoudersvergadering zal online worden gepubliceerd, tegelijkertijd met het Jaarverslag 2015 van DOCDATA N.V., op dinsdag 29 maart 2016.
Partijen die geïnteresseerd zijn in het verwerven van de eigendom van de aandelen van de beursholding worden vriendelijk verzocht om zo spoedig mogelijk contact op te nemen met de CFO, de heer Verstraeten (telefoonnummer: +31 (0)416 631 100; e-mail: [email protected]) of met de heer Van Mameren van NIBC Bank N.V. (telefoonnummer: +31 (0)70 342 9625; e-mail: [email protected]).
De huidige vierjarige benoemingstermijn als bestuurder van de heer Alting von Geusau, in dienst van DOCDATA N.V. sinds 19 oktober 1998 en sinds 1 maart 2002 in de functie van CEO, eindigt op de jaarlijkse Algemene Vergadering van Aandeelhouders te houden op 11 mei 2016. Vooruitlopend daarop zal de heer Alting von Geusau op 31 maart 2016 uit dienst treden als gevolg van de verkoop van de Docdata Groep en de IAI Groep. De Directie van DOCDATA N.V. zal daarna worden gevoerd door de heer Verstraeten, die in de functie van CFO verantwoordelijk zal zijn voor de verkoop dan wel opheffing van de beursholding. De heer Verstraeten zal uiterlijk op 31 december 2016 uit dienst treden, tenzij een eerdere afronding kan worden gerealiseerd.
De huidige vierjarige benoemingstermijn als commissaris van de heer Lindenbergh, in functie als commissaris van DOCDATA N.V. sinds 11 mei 2006, eindigt op de jaarlijkse Algemene Vergadering van Aandeelhouders te houden op 11 mei 2016 en daarmee exact tien jaren na diens aantreden. Aangezien de samenstelling van de Raad van Commissarissen als gevolg van de verkoop van de Docdata Groep en de IAI Groep in aantal wordt teruggebracht naar het wettelijk vereiste minimum aantal van drie commissarissen voor beursgenoteerde ondernemingen, zal de Raad van Commissarissen de heer Lindenbergh niet voor herbenoeming als commissaris voordragen aan de Algemene Vergadering. Na de Algemene Vergadering zal de Raad van Commissarissen worden gevormd door de drie andere commissarissen, de heren Koorstra, Schouwenaar en Elsendoorn, in ieder geval totdat alle bestuurlijke en financiële verplichtingen van de vennootschap zijn afgewikkeld.
De Directie van DOCDATA N.V. zal op de jaarlijkse Algemene Vergadering van Aandeelhouders, welke zal worden gehouden op woensdag 11 mei 2016, naar alle waarschijnlijkheid voorstellen om, overeenkomstig het bepaalde in artikel 28 en artikel 29 van de statuten van DOCDATA N.V., een besluit te nemen tot het uitkeren van een slotdividend aan de houders van gewone aandelen. De essentie van dit voorstel is afhankelijk van een eventuele voorstel dat de Directie in het kader van de afwikkeling van de beursholding tegelijkertijd ter goedkeuring aan de aandeelhouder zal voorleggen. De agenda voor deze aandeelhoudersvergadering zal online worden gepubliceerd, tegelijkertijd met het Jaarverslag 2015 van DOCDATA N.V., op dinsdag 29 maart 2016.
Het geplaatst aandelenkapitaal van DOCDATA N.V. bestond per 31 december 2015 uit 7.000.000 gewone aandelen met een nominale waarde van € 0,10 per aandeel. DOCDATA N.V. houdt momenteel (evenals per 31 december 2015) geen eigen gewone aandelen meer aan. Gewone aandelen in eigen bezit worden niet meegenomen in de bepaling van de winst per aandeel.
DOCDATA N.V. stelt de geconsolideerde jaarrekening op volgens de International Financial Reporting Standards zoals aanvaard binnen de Europese Unie (hierna genoemd IFRS-EU). Voor een overzicht van de belangrijkste waarderingsgrondslagen onder IFRS-EU wordt verwezen naar het Jaarverslag 2014, dat verkrijgbaar is bij de vennootschap en eveneens is te downloaden vanaf de corporate website van de onderneming, www.docdatanv.com. Vanaf 29 maart 2016 zal daar ook het Jaarverslag 2015 te downloaden zijn.
Voor een gedetailleerde behandeling van de jaarcijfers 2015 wordt verwezen naar de appendix 'Financial Information for the year ended 31 December 2015'.
Als gevolg van het afronden van de verkoop van de Docdata Groep en de IAI Groep in december 2015, zal het management van DOCDATA N.V. de jaarcijfers 2015 niet nader bespreken in een (in voorgaande jaren gebruikelijke) bijeenkomst voor financiële pers en analisten. Na de verkoop van de Docdata Groep en de IAI Groep bestaat de onderneming immers uitsluitend nog uit de beursholding DOCDATA N.V. en deze heeft verder geen operationele bedrijfsactiviteiten meer.
| 29 maart 2016 |
Publicatie Jaarverslag 2015 (online) |
|---|---|
| 13 april 2016 | Registratiedatum stemrecht |
| 20 april 2016 (*) |
Tussentijds bericht eerste kwartaal 2016 |
| 11 mei 2016 |
Jaarlijkse Algemene Vergadering van Aandeelhouders te Waalwijk |
| 14 juli 2016 (*) |
Publicatie halfjaarcijfers 2016 |
| 12 oktober 2016 (*) |
Tussentijds bericht derde kwartaal 2016 |
(*) datum onder voorbehoud, afhankelijk van toekomst beursnotering DOCDATA N.V.
De lidstaat van herkomst van DOCDATA N.V. voor de doeleinden van de Transparantierichtlijn van de Europese Unie (Richtlijn 2004/109/EC, zoals aangevuld) is Nederland.
Het beursgenoteerde DOCDATA N.V. bestaat na de in december 2015 afgeronde verkoop van de twee volledig autonome "lines of business" Docdata en IAI uitsluitend nog uit de vennootschap DOCDATA N.V. zelf.
Waalwijk, Nederland, 23 februari 2016
Verdere informatie: DOCDATA N.V., M.E.T. Verstraeten, CFO, Tel. 0416 631 100 Corporate website: www.docdatanv.com
Financial position before appropriation of profit.
| Reference | 31 December 2015 |
31 December 2014 |
|
|---|---|---|---|
| (in thousands) | € | € | |
| Assets | |||
| Property, plant and equipment | - | 25,685 | |
| Intangible assets | - | 6,999 | |
| Deferred tax assets | - | 677 | |
| Other investments | - | 11 | |
| Trade and other receivables Total non-current assets |
- - |
- 33,372 |
|
| Inventories | - | 10,991 | |
| Current income tax receivable | 6.10 | 1,217 | 1,345 |
| Trade and other receivables | 313 | 31,574 | |
| Cash and cash equivalents Total current assets |
6.7 | 31,817 33,347 |
21,849 65,759 |
| Total assets | 33,347 | 99,131 | |
| Equity | |||
| Share capital | 700 | 700 | |
| Share premium | 2,854 | 16,854 | |
| Translation reserves | - | (666) | |
| Reserve for own shares | - | 80 | |
| Retained earnings | (127,942) | 19,910 | |
| Unappropriated profits (Profit for the period) | 129,412 | 7,305 | |
| Total equity | 6.8 | 5,024 | 44,183 |
| Liabilities | |||
| Deferred tax liabilities | - | 794 | |
| Provisions | - | 328 | |
| Other non-current liabilities | - | 1,031 | |
| Total non-current liabilities | - | 2,153 | |
| Current income tax payable | - | 1,973 | |
| Payable to shareholders | 6.8 | 17,500 | - |
| Trade and other payables | 9,343 | 48,665 | |
| Bank overdraft | 6.7 | - | 1,331 |
| Provisions | 1,480 | 826 | |
| Total current liabilities | 28,323 | 52,795 | |
| Total liabilities | 28,323 | 54,948 | |
| Total equity and liabilities | 33,347 | 99,131 |
The 2014 consolidated income statement has been represented to reflect the correct presentation of the result from continuing operations and the result from discontinued operations.
| Reference | 2015 | 2014 represented | |||
|---|---|---|---|---|---|
| (in thousands, except for percentage figures and earnings per share) |
€ | % | € | % | |
| Revenue | - | - | - | - | |
| Cost of sales | - | - | - | - | |
| Gross profit | - | - | - | - | |
| Other operating income | - | - | - | - | |
| Selling expenses | - | - | - | - | |
| Administrative expenses | 6.9 | (7,193) | (5.6) | (1,056) | (14.5) |
| Other operating expenses | - | - | - | - | |
| Operating loss before financing result | (7,193) | (5.6) | (1,056) | (14.5) | |
| Financial income | 1,039 | 0.8 | 1,783 | 24.4 | |
| Financial expenses | (258) | (0.2) | (201) | (2.7) | |
| Net financing income | 781 | 0.6 | 1,582 | 21.7 | |
| Result before income tax | (6,412) | (5.0) | 526 | 7.2 | |
| Income tax | 6.10 | 1,114 | 0.9 | (91) | (1.2) |
| Result from continuing operations | (5,298) | (4.1) | 435 | 6.0 | |
| Profit from discontinued operations (net of income tax) |
6.11 | 134,710 | 104.1 | 6,870 | 94.0 |
| Profit for the period | 129,412 | 100.0 | 7,305 | 100.0 | |
| Attributable to equity holders of the parent | 129,412 | 100.0 | 7,305 | 100.0 | |
| Earnings per share | 18.49 | 1.05 |
The 2014 consolidated statement of cash flows has not been represented to present the net cash from operating, investing, or financing activities of discontinued operations individually. Instead, the consolidated statement of cash flows is derived from the 2014 annual report of DOCDATA N.V.
| Reference | 2015 | 2014 |
|---|---|---|
| (in thousands) | € | € |
| Cash flows from operating activities | ||
| Profit from continuing operations (2014: Profit for the period) Adjustments for: |
(5,298) | 7,305 |
| Depreciation and amortisation (including goodwill impairments) | 30 | 7,283 |
| Costs / (Gain) Performance Share Plan and delivered shares | (188) | 236 |
| Loss / (Gain) on sale of property, plant and equipment | - | (271) |
| Financial income | (1,039) | (235) |
| Financial expenses | 258 | 241 |
| Income tax expense | (1,114) | 2,696 |
| Cash flows from operating activities before changes in working capital and provisions |
(7,351) | 17,255 |
| (Increase) / decrease in trade and other receivables | (210) | (2,655) |
| (Increase) / decrease in inventories | - | (3,856) |
| Increase / (decrease) in trade and other payables | 5,245 | 6,970 |
| Increase / (decrease) in provisions and other non-current | ||
| liabilities | 1,480 | (721) |
| Cash generated from / spent for the operations | (836) | 16,993 |
| Interest paid | (258) | (241) |
| Interest received | 733 | 183 |
| Income taxes paid | (123) | (4,530) |
| Income taxes received | - | 2,518 |
| Net cash from operating activities of discontinued operations | 17,582 | - |
| Net cash from operating activities 6.8 |
17,098 | 14,923 |
| Cash flows from investing activities | ||
| Proceeds from sale of subsidiaries | 173,533 | 281 |
| Acquisition of property, plant and equipment | (2) | (10,117) |
| Acquisition of intangible assets | - | (1,897) |
| Proceeds from sale of property, plant and equipment | - | 1,093 |
| Net cash from investing activities of discontinued operations | (8,051) | - |
| Net cash from investing activities 6.8 |
165,480 | (10,640) |
| Cash flows from financing activities | ||
| Dividends and interim distributions paid | (150,812) | (4,851) |
| Own shares bought | (1,041) | (1,127) |
| Own shares sold | 304 | - |
| Net cash from financing activities of discontinued operations | 9,972 | - |
| Net cash from financing activities 6.8 |
(141,577) | (5,978) |
| Net increase / (decrease) in non-restricted cash and cash | ||
| equivalents | 41,001 | (1,695) |
| Cash and cash equivalents at the beginning of the period | - | 6,704 |
| (Repayment of) / Proceeds from bank overdraft | (9,225) | 1,331 |
| Restricted cash and cash equivalents 6.7 |
- | 15,355 |
| Effect of exchange rate fluctuations on cash held | 41 | 154 |
| Cash and cash equivalents at the end of the period | 31,817 | 21,849 |
| Share capital |
Share premium |
Translation reserves |
Reserve for own shares and share based pay ments costs |
Retained earnings |
Unappro priated profits |
Total equity |
|
|---|---|---|---|---|---|---|---|
| (in thousands) | € | € | € | € | € | € | € |
| 2014 | |||||||
| Balance at 1 January 2014 | 700 | 16,854 | (523) | 441 | 16,626 | 8,665 | 42,763 |
| Total comprehensive income | |||||||
| Profit for the period | - | - | - | - | - | 7,305 | 7,305 |
| Unrealised exchange rate results | - | - | (143) | - | - | - | (143) |
| Total comprehensive income | - | - | (143) | - | - | 7,305 | 7,162 |
| Transactions with owners of the Company | |||||||
| Dividend distribution | - | - | - | - | - | (4,851) | (4,851) |
| Appropriation of result | - | - | - | - | 3,814 | (3,814) | - |
| Own shares bought | - | - | - | (1,127) | - | - | (1,127) |
| Costs Performance Share Plan | - | - | - | 236 | - | - | 236 |
| Realised reserve for own shares | - | - | - | 530 | (530) | - | - |
| Total transactions with owners | - | - | - | (361) | 3,284 | (8,665) | (5,742) |
| Balance at 31 December 2014 | 700 | 16,854 | (666) | 80 | 19,910 | 7,305 | 44,183 |
| 2015 | |||||||
| Balance at 1 January 2015 | 700 | 16,854 | (666) | 80 | 19,910 | 7,305 | 44,183 |
| Total comprehensive income | |||||||
| Profit for the period | - | - | - | - | - | 129,412 | 129,412 |
| Realised exchange rate results | - | - | 666 | - | - | - | 666 |
| Total comprehensive income | - | - | 666 | - | - | 129,412 | 130,078 |
| Transactions with owners of the Company | |||||||
| Dividend distribution | - | - | - | - | - | (3,812) | (3,812) |
| Appropriation of result | - | - | - | - | 3,493 | (3,493) | - |
| Interim distribution | - | (14,000) | - | - | (150,500) | - | (164,500) |
| Own shares bought | - | - | - | (1,041) | - | - | (1,041) |
| Own shares sold | - | - | - | 304 | - | - | 304 |
| Costs Performance Share Plan | - | - | - | (188) | - | - | (188) |
| Realised reserve for own shares | - | - | - | 845 | (845) | - | - |
| Total transactions with owners | - | (14,000) | - | (80) (147,852) | (7,305) | (169,237) | |
| Balance at 31 December 2015 | 700 | 2,854 | - | - | (127,942) 129,412 | 5,024 | |
| 2015 | 2014 | |
|---|---|---|
| (in thousands) | € | € |
| Foreign exchange translation differences, net of tax | 666 | (143) |
| Income / (Expense) recognised directly in equity | 666 | (143) |
| Profit for the period | 129,412 | 7,305 |
| Total comprehensive income | 130,078 | 7,162 |
| Attributable to equity holders of the parent | 130,078 | 7,162 |
The financial information is prepared in accordance with International Financial Reporting Standards as adopted by the European Union (hereafter "IFRS-EU") and its interpretations adopted by the International Accounting Standards Board (IASB).
DOCDATA N.V. (referred to as "DOCDATA" or the "Company") is a company domiciled in Waalwijk, the Netherlands. The consolidated financial statements of DOCDATA N.V. as at and for the year ended 31 December 2014 comprise DOCDATA N.V. and its subsidiaries (together referred to as the "Group") and the Group's interest in associates and jointly controlled entities. The consolidated financial information of DOCDATA N.V. as at and for the year ended 31 December 2015 only comprise DOCDATA N.V., as the Company neither does hold any shares in subsidiaries, nor has any interest in associates and jointly controlled entities, after completion per 18 December 2015 of the sale of the Docdata Group to Ingram Micro Regent B.V. (through the sale of all shares in the capital of the intermediate holding companies DOCdata Nederland B.V. and DOCdata International B.V.) and completion per 22 December 2015 of the sale of the IAI Group to ASSA ABLOY Nederland Holding B.V. (through the sale of all shares in the capital of the company IAI industrial systems B.V.).
The consolidated financial statements of the Group as at and for the year ended 31 December 2015 will be published online on 29 March 2016. The consolidated financial statements of the Group as at and for the year ended 31 December 2014 are available upon request from the Company's registered office at Energieweg 2, 5145 NW in Waalwijk, the Netherlands, or can be downloaded from the Company's corporate website, www.docdatanv.com.
This consolidated financial information does not include all of the information required for full annual financial statements, and should therefore be read in conjunction with the consolidated financial statements of the Group as at and for the year ended 31 December 2014.
The consolidated financial statements of the Group are prepared in accordance with the International Financial Reporting Standards as adopted by the European Union ("IFRS-EU"). The accounting policies applied by the Group in this consolidated financial information are the same as those applied by the Group in its consolidated financial statements as at and for the year ended 31 December 2014. For a summary of the significant accounting policies under IFRS-EU, please refer to the Group's Annual Report for the year ended 31 December 2014.
In the opinion of the management, this consolidated financial information include all adjustments necessary for a fair presentation of the financial position, operating results and cash flows of all reporting periods herein.
In the consolidated financial information for the year ended 31 December 2015, non-recurring items have been recorded for the following topics:
Non-recurring items were recorded in the consolidated financial statements for the year ended 31 December 2014, as included in the 2014 profit from discontinued operations, for the following topics:
In the consolidated financial information for the year ended 31 December 2015 and the consolidated financial statements for the year ended 31 December 2014, the following treatment has been applied for the following incorporations:
§ docdata payments Ltd.: effective 7 April 2015, the former UK subsidiary docdata payments Ltd. has formally been liquidated and dissolved, and was removed from the register by UK Company House;
§ docdata commerce Ltd.: effective 27 February 2015, the former UK subsidiary docdata commerce Ltd. has formally been liquidated and dissolved, and was removed from the register by UK Company House;
| 31 December | 31 December | |
|---|---|---|
| 2015 | 2014 | |
| (in thousands) | € | € |
| Net cash position | 31,817 | 5,163 |
| Bank overdraft | - | (1,331) |
| Non-restricted cash and cash equivalents | 31,817 | 6,494 |
| Restricted cash and cash equivalents | - | 15,355 |
| Total cash and cash equivalents | 31,817 | 21,849 |
Restricted cash and cash equivalents per 31 December 2014 only consisted of the restricted cash and cash equivalents recorded in the balance sheet of Stichting foundation docdata payments, representing cash received from customers on behalf of the Docdata Payments merchants in the bank accounts of Stichting foundation docdata payments which shall have to be paid (net of charged Docdata Payments fees) to the merchants without any disposition of this cash balance to the Group.
The bank overdraft balance of € 1.3 million per 31 December 2014 concerned the use of the Group's credit facility with Deutsche Bank Nederland N.V. in the Netherlands, which could not be netted with the available (non-restricted) bank balances held by the Group at Deutsche Bank AG and Commerzbank AG in Germany, National Westminster Bank Plc. in the United Kingdom, Deutsche Bank SpA in Italy and BRE Bank SA in Poland. This balance has been repaid in 2015.
The Annual General Meeting of Shareholders held on 12 May 2015 approved the proposal to distribute a dividend of € 0.55 per ordinary share outstanding, which had a decreasing impact of € 3.8 million on retained earnings within the equity of the Company in the year ended 31 December 2015. The dividend was paid by the Company on 20 May 2015 from the net cash available.
The Extraordinary General Meeting of Shareholders held on 16 December 2015 approved the (conditional) proposal to distribute an amount of € 21.00 per ordinary share outstanding (provided that the sale of the Docdata Group would be completed), of which € 2.00 per share as a share premium distribution (€ 14 million), € 17.00 per share as an interim-dividend out of the expected profit for the year ended 31 December 2015 (€ 119 million) and € 2.00 per share as a dividend from the retained earnings (€ 14 million). This total interim-distribution had a decreasing impact of € 147 million on the equity of the Company in 2015 and was paid by the Company on 29 December 2015 from the net cash available at the time after completion of the sale of the Docdata Group.
Additionally, the Extraordinary General Meeting of Shareholders held on 16 December 2015 also approved the (conditional) proposal to distribute an amount of € 2.50 per ordinary share outstanding (provided that the sale of the IAI Group would be completed), which had a decreasing impact of € 17.5 million on retained earnings within the equity of the Company in the year ended 31 December 2015. This interim-distribution has been recorded as a liability to the shareholders under Trade and other payables in the balance sheet at 31 December 2015 and was paid by the Company on 11 January 2016 from the net cash available at 31 December 2015.
The Performance Shares granted conditionally in 2012 vested at 1 June 2015 with a vesting percentage of 84.63%, which was based on the average annual Total Shareholder Return growth realised over the three-year performance period covering the years 2012, 2013 and 2014. For a total number of 62,387 outstanding Performance Shares the Company has delivered 52,805 own shares. As the Company owned 20,731 shares per beginning of the financial year, additional own shares were bought by the Company through a broker on the Euronext Amsterdam stock market in the weeks following the publication of the 2014 financial results (i.e. total number of shares bought: 49,269 shares; purchased in two tranches on 27 February 2015 and 6 March 2015; average purchase price: € 21.13 per share). At 30 June 2015, the Company still held 13,829 own shares, after transferring 3,366 shares for the 2014 bonus to the CEO and CFO after approval of the 2014 Remuneration report by the Annual General Meeting of Shareholders in May 2015. These shares were sold on 16 October 2015 through an external broker at the Euronext Amsterdam stock market at a price of € 22.00 and thus generated proceeds in the amount of € 304 thousand, which was recorded directly in equity. Since that date, the Company no longer holds own shares.
After the approval by the Extraordinary General Meeting of Shareholders held on 16 December 2015 of the sale of the Docdata Group and the IAI Group, the DOCDATA N.V. Performance Share Plan was terminated with immediate effect and the participants to the Performance Share Plan holding outstanding unvested awards were compensated by means of a cash settlement for the loss of their rights to the Performance Shares granted to them in the years 2013, 2014 and 2015. This cash settlement has been determined based on the actual performance realised at the time of the termination. A total number of 91,070 Performance Shares were outstanding at the termination date, which were granted conditionally (i) in 2013 (36,515 Performance Shares; original vesting date: 16 May 2016; vesting percentage at termination date: 100.20%; average annual TRS growth at termination date: 22.7%), (ii) in 2014 (26,076 Performance Shares; original vesting date: 15 May 2017; vesting percentage at termination date: 94.16%; average annual TRS growth at termination date: 21.8%) and (iii) in 2015 (28,479 Performance Shares; original vesting date: 14 May 2018; vesting percentage at termination date: 94.72%; average annual TRS growth at termination date: 21.9%). In total, a cash settlement in the amount of € 2 million, fully accounted for as Administrative expenses in the 2015 consolidated income statement, has been paid to all participants as gross (taxable) income through the December 2015 payroll. For the members of the DOCDATA N.V. Management Board, a 'claw back discount' was voluntarily applied when settling the outstanding unvested awards in cash, by using the provisions of Article 2:135, sec. 7 of the Dutch Civil Code, representing for a total discount of € 73 thousand.
The own shares required at vesting of Performance Share Plans in previous years were bought by the Company, if and when needed in the future, through an external broker at the Euronext Amsterdam stock market. The 'Reserve for own shares' balance in equity per 31 December 2014 amounted to € 80 thousand (credit), representing the total of the purchase price paid for the own shares the Company holds, and all costs recorded against income for the Performance Shares granted in 2012, 2013 and 2014 as at 31 December 2014. Each time when Performance Shares vested or own shares were sold, the 'Reserve for own shares and share based payments costs' balance was partially released to retained earnings for the corresponding relative amount related to those vested Performance Shares or sold own shares. In the year ended 31 December 2015, the Reserve for own shares and share based payments costs has been fully realised as the Company does not hold any Performance Shares or own shares anymore at 31 December 2015.
In the year ended 31 December 2015, the Group realised a net cash from operating activities of € 17.1 million, consisting of net cash from operating activities from discontinued operations (€ 17.6 million) and a negative net cash from operating activities from DOCDATA N.V. (-/- € 0.5 million). A total amount of € 173.5 million in cash proceeds was received in 2015 from the sale of the Docdata Group (€ 160.4 million) and the IAI Group (€ 13.1 million, excluding repayment of intercompany loans provided by DOCDATA N.V. to the IAI Group). The Group has invested and
paid in the year ended 31 December 2015 a total (net) amount of € 8 million for discontinued operations (€ 5.5 million for capital expenditure in property, plant and equipment, € 4.5 million for capital expenditure in intangibles, minus proceeds of € 2 million for the sale of property, plant and equipment). Furthermore, intercompany loans provided by the Company to the IAI Group for a total amount of € 10 million were repaid by ASSA ABLOY Nederland Holding B.V. upon completion of the sale transaction of the IAI Group. Finally, the Company has purchased and sold own shares for a net amount of € 0.7 million, repaid the bank overdraft outstanding per 31 December 2014 of € 9.2 million and has paid dividends and interim-distributions for a total amount of € 150.8 million in 2015. As a result, the net cash position of the Company amounts to € 31.8 million at 31 December 2015. With this cash, the Company has funded the payment in the first months of 2016 of the January 2016 interim-distribution of € 17.5 million, as well as dividend withholding taxes of € 5.2 million withheld by the Company on the December 2015 interim-distribution of € 21.00 per share; furthermore, payments for creditors and wage taxes were processed for a total amount of almost € 2.5 million. Currently, the Company still holds an amount in cash of approximately € 6.5 million, which will be required to fund the settlement of all remaining liabilities of the Company, including any potential final dividend out of the 2015 profit which might be proposed to the Annual General Meeting of Shareholders to be held in May 2016.
Total administrative expenses of the Company in the amount of € 7.2 million for the year ended 31 December 2015, include transaction costs related to the sale of the Docdata Group and the IAI Group for a total amount of € 6.3 million. These transaction costs contain costs for the termination and final settlement of the employment contracts of three employees (CEO, CFO and Corporate Controller) of the Company (€ 2.1 million, including employer's taxes), costs for the termination and cash settlement of the DOCDATA N.V. Performance Share Plan (€ 2.0 million), advisory and consultancy costs (€ 2.1 million) and other shareholder costs (€ 0.1 million).
The income tax gain of € 1.1 million in 2015 reflects the tax effect on the taxable loss for the year ended 31 December 2015 of the Dutch fiscal entity headed by DOCDATA N.V., which can be carried back to the taxable profit for the year ended 31 December 2014. In the balance sheet at 31 December 2015, this carry back facility for the 2015 NOL (net operating loss) is represented by the current income tax receivable in the amount of € 1.2 million, which is valued at the full amount paid for corporate income taxes on the actual 2014 tax return of the fiscal entity DOCDATA N.V.
At 31 December 2015, the Dutch fiscal entity only consists of the legal entity DOCDATA N.V. The Dutch subsidiaries of the Docdata Group, which were previously part of the Dutch fiscal entity headed by DOCDATA N.V., were disconnected per the 18 December 2015 completion date of the sale of the Docdata Group after obtaining approval of the application of this date from the Dutch tax authorities. Similarly, the Dutch subsidiaries of the IAI Group, previously part of this fiscal entity, were disconnected per 22 December 2015 after obtaining approval of this date from the Dutch tax authorities.
Profit from discontinued operations (net of income tax) of the Group in the amount of € 134.7 million for the year ended 31 December 2015, include the profit realised on the sale of the Docdata Group (€ 121.1 million) and the IAI Group (€ 12.2 million) and the results for the period from 1 January 2015 until the completion dates of the sale of the Docdata Group, 18 December 2015 (€ 6.8 million profit (after tax) for the period), and the IAI Group, 22 December 2015 (€ 5.4 million loss (after tax) for the period).
The 2015 segment key financial results of the Docdata Group and the IAI Group fully relate to the results from discontinued operations of each of these Groups, while the 2014 segment key financial results relate for both Groups to the published segment reporting derived from the disclosures in the 2014 annual report of DOCDATA N.V., which includes allocated holding expenses.
| 2015 (1 January until 18 December) |
2014 (1 January until 31 December) |
|||
|---|---|---|---|---|
| (in thousands, except for percentage figures) | € | % | € | % |
| Revenue | 166,287 | 100.0 | 147,105 | 100.0 |
| Gross profit (margin as a % of revenue) | 28,598 | 17.2 | 30,483 | 20.7 |
| Selling and administrative expenses Other operating income and expenses |
(18,957) 473 |
(11.4) 0.3 |
(20,204) (801) |
(13.7) (0.5) |
| EBITDA | 15,686 | 9.4 | 15,909 | 10.8 |
| Operating profit before financing result (EBIT) | 10,114 | 6.1 | 9,478 | 6.4 |
| Net profit of the Group | 6,767 | 4.1 | 6,861 | 4.7 |
| 2015 (1 January until 22 December) |
2014 (1 January until 31 December) |
|||
|---|---|---|---|---|
| (in thousands, except for percentage figures) | € | % | € | % |
| Revenue | 11,922 | 100.0 | 21,602 | 100.0 |
| Gross profit / (loss) (margin as a % of revenue) | (1,079) | (9.1) | 5,225 | 24.2 |
| Selling and administrative expenses Other operating income and expenses |
(4,139) (951) |
(34.7) (8.0) |
(4,734) 38 |
(21.9) 0.2 |
| EBITDA | (4,335) | (36.4) | 1,381 | 6.4 |
| Operating profit before financing result (EBIT) | (6,169) | (51.7) | 529 | 2.5 |
| Net profit / (loss) for the Group | (5,372) | (45.1) | 444 | 2.1 |
Waalwijk (the Netherlands), 23 February 2016
*************************
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.